101 related articles for article (PubMed ID: 23958516)
21. Mineralocorticoid receptor modulators: a patent review (2007 - 2012).
Collin M; Niemann F; Jaisser F
Expert Opin Ther Pat; 2014 Feb; 24(2):177-83. PubMed ID: 24215301
[TBL] [Abstract][Full Text] [Related]
22. Structural and biochemical mechanisms for the specificity of hormone binding and coactivator assembly by mineralocorticoid receptor.
Li Y; Suino K; Daugherty J; Xu HE
Mol Cell; 2005 Aug; 19(3):367-80. PubMed ID: 16061183
[TBL] [Abstract][Full Text] [Related]
23. Design and synthesis of nonsteroidal progesterone receptor antagonists based on C,C'-diphenylcarborane scaffold as a hydrophobic pharmacophore.
Fujii S; Yamada A; Nakano E; Takeuchi Y; Mori S; Masuno H; Kagechika H
Eur J Med Chem; 2014 Sep; 84():264-77. PubMed ID: 25036787
[TBL] [Abstract][Full Text] [Related]
24. Novel pyrrole-containing progesterone receptor modulators.
Collins MA; Hudak V; Bender R; Fensome A; Zhang P; Miller L; Winneker RC; Zhang Z; Zhu Y; Cohen J; Unwalla RJ; Wrobel J
Bioorg Med Chem Lett; 2004 May; 14(9):2185-9. PubMed ID: 15081005
[TBL] [Abstract][Full Text] [Related]
25. Design of LFA-1 antagonists based on a 2,3-dihydro-1H-pyrrolizin-5(7aH)-one scaffold.
Dodd DS; Sheriff S; Chang CJ; Stetsko DK; Phillips LM; Zhang Y; Launay M; Potin D; Vaccaro W; Poss MA; McKinnon M; Barrish JC; Suchard SJ; Murali Dhar TG
Bioorg Med Chem Lett; 2007 Apr; 17(7):1908-11. PubMed ID: 17291752
[TBL] [Abstract][Full Text] [Related]
26. Structure-activity relationships and key structural feature of pyridyloxybenzene-acylsulfonamides as new, potent, and selective peroxisome proliferator-activated receptor (PPAR) γ Agonists.
Rikimaru K; Wakabayashi T; Abe H; Tawaraishi T; Imoto H; Yonemori J; Hirose H; Murase K; Matsuo T; Matsumoto M; Nomura C; Tsuge H; Arimura N; Kawakami K; Sakamoto J; Funami M; Mol CD; Snell GP; Bragstad KA; Sang BC; Dougan DR; Tanaka T; Katayama N; Horiguchi Y; Momose Y
Bioorg Med Chem; 2012 May; 20(10):3332-58. PubMed ID: 22503460
[TBL] [Abstract][Full Text] [Related]
27. 7-aryl 1,5-dihydro-benzo[e][1,4]oxazepin-2-ones and analogs as non-steroidal progesterone receptor antagonists.
Zhang P; Kern JC; Terefenko EA; Fensome A; Unwalla R; Zhang Z; Cohen J; Berrodin TJ; Yudt MR; Winneker RC; Wrobel J
Bioorg Med Chem; 2008 Jul; 16(13):6589-600. PubMed ID: 18504132
[TBL] [Abstract][Full Text] [Related]
28. Aldosterone antagonists. 1. Synthesis and biological activities of 11 beta,18-epoxypregnane derivatives.
Kamata S; Haga N; Mitsugi T; Kondo E; Nagata W; Nakamura M; Miyata K; Odaguchi K; Shimizu T; Kawabata T
J Med Chem; 1985 Apr; 28(4):428-33. PubMed ID: 2984418
[TBL] [Abstract][Full Text] [Related]
29. Parallel synthesis and SAR study of novel oxa-steroids as potent and selective progesterone receptor antagonists.
Kang FA; Guan J; Jain N; Allan G; Linton O; Tannenbaum P; Chen X; Xu J; Zhu P; Gunnet J; Demarest K; Lundeen S; Sui Z
Bioorg Med Chem Lett; 2007 May; 17(9):2531-4. PubMed ID: 17317167
[TBL] [Abstract][Full Text] [Related]
30. Structural determinants of ligand binding to the mineralocorticoid receptor.
Huyet J; Pinon GM; Fay MR; Rafestin-Oblin ME; Fagart J
Mol Cell Endocrinol; 2012 Mar; 350(2):187-95. PubMed ID: 21820032
[TBL] [Abstract][Full Text] [Related]
31. Predicting the relative binding affinity of mineralocorticoid receptor antagonists by density functional methods.
Roos K; Hogner A; Ogg D; Packer MJ; Hansson E; Granberg KL; Evertsson E; Nordqvist A
J Comput Aided Mol Des; 2015 Dec; 29(12):1109-22. PubMed ID: 26572910
[TBL] [Abstract][Full Text] [Related]
32. Design and synthesis of novel 3-substituted-indole derivatives as selective H3 receptor antagonists and potent free radical scavengers.
Tang L; Zhao L; Hong L; Yang F; Sheng R; Chen J; Shi Y; Zhou N; Hu Y
Bioorg Med Chem; 2013 Oct; 21(19):5936-44. PubMed ID: 23978359
[TBL] [Abstract][Full Text] [Related]
33. Discovery of Apararenone (MT-3995) as a Highly Selective, Potent, and Novel Nonsteroidal Mineralocorticoid Receptor Antagonist.
Iijima T; Katoh M; Takedomi K; Yamamoto Y; Akatsuka H; Shirata N; Nishi A; Takakuwa M; Watanabe Y; Munakata H; Koyama N; Ikeda T; Iguchi T; Kato H; Kikkawa K; Kawaguchi T
J Med Chem; 2022 Jun; 65(12):8127-8143. PubMed ID: 35652647
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and structure-activity relationship of novel 6-aryl-1,4-dihydrobenzo[d][1,3]oxazine-2-thiones as progesterone receptor modulators leading to the potent and selective nonsteroidal progesterone receptor agonist tanaproget.
Fensome A; Bender R; Chopra R; Cohen J; Collins MA; Hudak V; Malakian K; Lockhead S; Olland A; Svenson K; Terefenko EA; Unwalla RJ; Wilhelm JM; Wolfrom S; Zhu Y; Zhang Z; Zhang P; Winneker RC; Wrobel J
J Med Chem; 2005 Aug; 48(16):5092-5. PubMed ID: 16078826
[TBL] [Abstract][Full Text] [Related]
35. Biological activity and ligand binding mode to the progesterone receptor of A-homo analogues of progesterone.
Alvarez LD; Dansey MV; Martí MA; Bertucci PY; Di Chenna PH; Pecci A; Burton G
Bioorg Med Chem; 2011 Mar; 19(5):1683-91. PubMed ID: 21315613
[TBL] [Abstract][Full Text] [Related]
36. Identification of Morpholino-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-ones as Nonsteroidal Mineralocorticoid Antagonists.
Piotrowski DW; Futatsugi K; Casimiro-Garcia A; Wei L; Sammons MF; Herr M; Jiao W; Lavergne SY; Coffey SB; Wright SW; Song K; Loria PM; Banker ME; Petersen DN; Bauman J
J Med Chem; 2018 Feb; 61(3):1086-1097. PubMed ID: 29300474
[TBL] [Abstract][Full Text] [Related]
37. Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile.
Sasagawa S; Shimizu Y; Kami H; Takeuchi T; Mita S; Imada K; Kato S; Mizuguchi K
Steroids; 2008 Feb; 73(2):222-31. PubMed ID: 18061638
[TBL] [Abstract][Full Text] [Related]
38. Design, Synthesis and Biological Evaluation of Novel Nonsteroidal Progesterone Receptor Antagonists Based on Phenylamino-1,3,5-triazine Scaffold.
Kaitoh K; Nakatsu A; Mori S; Kagechika H; Hashimoto Y; Fujii S
Chem Pharm Bull (Tokyo); 2019; 67(6):566-575. PubMed ID: 31155562
[TBL] [Abstract][Full Text] [Related]
39. SAR studies of 6-aryl-1,3-dihydrobenzimidazol-2-ones as progesterone receptor antagonists.
Terefenko EA; Kern J; Fensome A; Wrobel J; Zhu Y; Cohen J; Winneker R; Zhang Z; Zhang P
Bioorg Med Chem Lett; 2005 Aug; 15(15):3600-3. PubMed ID: 15978807
[TBL] [Abstract][Full Text] [Related]
40. Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines.
Arhancet GB; Woodard SS; Dietz JD; Garland DJ; Wagner GM; Iyanar K; Collins JT; Blinn JR; Numann RE; Hu X; Huang HC
J Med Chem; 2010 May; 53(10):4300-4. PubMed ID: 20408553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
